Thursday, May 26, 2011

Rigel Pharmaceuticals to raise $25M in stock sale

Rigel Pharmaceuticals Inc. registered with regulators for a stock sale worth up to $25 million.
The South San Francisco company (NASDAQ: RIGL) is working on a treatment for rheumatoid arthritis along with AstraZeneca AB, and also an inhaled treatment for allergic asthma.

No comments:

Post a Comment